Meena .

Company: Stoke Therapeutics

Job title: SVP

Seminars:

9:00 am Workshop A: Streamlining Preclinical Assessment from Dish, to Rodent, to NHP for Improved Oligonucleotide Translation in the CNS 9:00 am

As oligonucleotide therapeutics advance in neurodegeneration and ophthalmology, optimizing in vitro and in vivo assays is critical to improving delivery, minimizing off-target effects, and ensuring translatability into clinical success. This workshop will explore best practices in assay development for RNA-based therapeutics, from high-throughput screening (HTS) strategies to NHP validation. Join this session to: Refine in…Read more

day: Pre-Conference Workshop Day - Track A P1

Panel Discussion: The Future of Oligonucleotide Therapeutics: Where Will the Field Be in 5 Years? 4:00 pm

How will advances in conjugation strategies, nanoparticle formulations, and tissue-specific targeting improve oligonucleotide biodistribution and efficacy? Beyond ALS, Huntington’s Disease & Alzheimer’s. What new indications, such as neurogenetic, epilepsies, neurodevelopmental and neuropsychiatric, are emerging for oligonucleotide-based therapies? What hurdles remain in scaling oligonucleotide production, and how will evolving regulatory frameworks shape the clinical and commercial…Read more

day: Day 2